(VIANEWS) – The NASDAQ ended the session with Moderna (MRNA) rising 14.1% to $113.47 on Tuesday while NASDAQ dropped 1.63% to $14,765.94.
Moderna’s last close was $99.45, 52.07% under its 52-week high of $207.51.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a strategic partnership with Caris Life Sciences to advance mRNA-Based oncology therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Moderna has a trailing twelve months EPS of $-9.23.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.04%.
Yearly Top and Bottom Value
Moderna’s stock is valued at $113.47 at 17:09 EST, way under its 52-week high of $207.51 and way higher than its 52-week low of $62.55.
Volatility
Moderna’s last week, last month’s, and last quarter’s current intraday variation average was 0.73%, 1.19%, and 2.60%.
Moderna’s highest amplitude of average volatility was 2.04% (last week), 2.66% (last month), and 2.60% (last quarter).
More news about Moderna (MRNA).
